Docket No.: PF-0421-2 DIV

For the Examiner's convenience, all pending claims are listed below. Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made."

- 1. An isolated polypeptide selected from the group consisting of:
- a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5,
- b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5,
- c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5, and
- d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.
 - 10. An isolated antibody which specifically binds to a polypeptide of claim 1.
- 29. A diagnostic test for a condition or disease associated with the expression of APOP in a biological sample comprising the steps of:
- a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
 - 30. The antibody of claim 10, wherein the antibody is:
 - a) a chimeric antibody,
 - b) a single chain antibody,
 - c) a Fab fragment,
 - d) a F(ab'), fragment, or
 - e) a humanized antibody.
 - 31. A composition comprising an antibody of claim 10 and an acceptable excipient.

Docket No.: PF-0421-2 DIV

32. A method of diagnosing a condition or disease associated with the expression of APOP in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

- 33. A composition of claim 31, wherein the antibody is labeled.
- 34. A method of diagnosing a condition or disease associated with the expression of APOP in a subject, comprising administering to said subject an effective amount of the composition of claim 33.
- 35. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:
- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
 - b) isolating antibodies from said animal; and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.
 - 36. An antibody produced by a method of claim 35.
 - 37. A composition comprising the antibody of claim 36 and a suitable carrier.
- 38. A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising:
- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
 - b) isolating antibody producing cells from the animal;
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
 - d) culturing the hybridoma cells; and

Docket No.: PF-0421-2 DIV

e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.

- 39. A monoclonal antibody produced by a method of claim 38.
- 40. A composition comprising the antibody of claim 39 and a suitable carrier.
- 41. The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.
- 42. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.
- 43. A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5 in a sample, comprising the steps of:
- a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5 in the sample.
- 44. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5 from a sample, the method comprising:
- a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
- b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.
 - 51. An isolated antibody which specifically binds to a polypeptide of SEQ ID NO:3.
 - 52. An isolated antibody which specifically binds to a polypeptide of SEQ ID NO:5.